Single-Blind Study of STAT-205 in Mild COVID-19

Status unconfirmed · Phase 1 · Has a placebo group

Conditions studied: COVID-19

In brief

This is a randomized, single blind, study. Males and females meeting inclusion criteria who have symptoms of mild COVID-19 and in whom a positive PCR result for SARS-CoV-2 is obtained may be enrolled to the study treatment within 72 hours of the positive PCR result. Eligible patients are those considered to be at high risk for COVID-19 disease progression. This includes patients ≥ 65 years of age or with any one or more of certain medical conditions including: cancer, COPD, cardiovascular disease, immunocompromised state resulting from solid organ transplant, obesity, sickle cell disease, history of smoking, and diabetes.

Key facts

Study ID

NCT04708327

Run by

Cytocom, Inc.

People needed

24

Starts

2021-12-05

Expected to finish

2022-09-30

Last updated by the study team

2021-12-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >18 at the time of informed consent
• Able to understand and provide informed consent in either English or Spanish
• At high risk for COVID-19 disease progression by fulfilling at least ONE of the following criteria at Screening:
• Age ≥65 years
• Has a diagnosis of chronic pulmonary disease requiring daily treatment (e.g. COPD, chronic persistent asthma, cystic fibrosis, chronic bronchitis)
• Has a diagnosis of chronic heart disease
• Has a diagnosis of diabetes (type 1 or type 2) requiring oral therapy and/or insulin therapy
• Has hypertension requiring at least one oral medication for treatment
• Has a body mass index (BMI) of ≥33 kg/m2
• Has an immunocompromising disease (e.g. HIV infection with CD4 count < 200 cells/mm3)
• Is immunocompromised due to daily treatment with ≥20 mg of prednisone or equivalent
• Has received a solid organ transplant
• Has any chronic condition that, in the opinion of the investigator, places the patient at increased risk for progression of COVID-19
• Documentation of positive diagnostic test for SARS-CoV-2 (confirmed by PCR assay or other approved diagnostic test) performed with a sample from nares or saliva, collected within 7 days of the Screening visit.
• Is symptomatic for COVID-19 for no more than 7 days prior to the Screening visit
• Has a WHO Clinical Progression Scale (WHOb 2020) score of either '2' or '3' at Screening and Randomization
• Has at least one of the following symptoms at the Screening visit that are new in onset, or if present by history, has worsened during the 7 days prior to Screening:
• · fever, chills, myalgia, arthralgia, headache, fatigue, cough, sore throat, nasal congestion, nausea, vomiting, diarrhea, anosmia or dysosmia, ageusia or dysgeusia
• If female of child-bearing potential, must agree to use of 2 forms of contraception from Screening to end of the study. Males must agree to use 2 forms of contraception from screening to the end of the study if their partners are of childbearing potential. Acceptable methods of birth control which must be used together are:
• Oral or injectable contraceptive and condom, or
• IUD and condom, or
• Diaphragm with spermicide and condom.
• Agrees to participate in all in-person visits and remote or home visits as required by the protocol and to provide updated contact information, as necessary.

You may not qualify if…

• Has a WHO Clinical Progression Scale (WHOb 2020) score of '4' or higher at Screening or Enrollment
• Previous hypersensitivity or allergic reactions to naltrexone
• Women who are pregnant or lactating or expecting to become pregnant
• Drugs of abuse screen positive for opiates
• Patients with history of moderate to severe renal impairment (estimated creatinine clearance < 50 mL/min) or hepatic impairment (Child-Pugh C)
• Serum ALT or AST value > 3 times the ULN at Screening
• Serum creatinine value > 2 times the ULN at Screening, or requires renal dialysis
• Hematology results at Screening showing any one of the following: WBC <2000 cells/mm3 or platelet count <100,000 cells/mm3 or hemoglobin <8.5 Gm/dL
• Currently receiving chronic daily opioid therapy
• Use of tocilizumab or other immunomodulator therapy directed to treatment or prevention of COVID-19
• History of active substance abuse within the 2 years prior to Screening
• Participation in another clinical trial investigating a treatment for COVID-19
• Currently hospitalized or under immediate consideration for hospitalization (for any medical reason) at the Screening visit
• At Screening, has new onset of dyspnea (shortness of breath) or, if previously diagnosed with a chronic lung condition, the severity of dyspnea has increased over patient's historical baseline condition (increased dyspnea should be present continually and not intermittent)
• Measurement of oxygen saturation at Screening is < 94% on ambient room air
• Shares a household with a patient currently enrolled in this protocol
• Patients who refuse biomarker blood draws

Where it is running

• Loma Linda University — Loma Linda, California, United States (enrolling)
• Clinical Research Center of Florida — Pompano Beach, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.